Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Successful £16.15 million Placing & Close of Accelerated Bookbuild
Manchester, UK – 5 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to announce that further to the announcement made yesterday at 5.13 p.m., the Bookbuild has now closed and following strong demand, the Company expects to raise gross proceeds of £16.15 million (approximately £15.0 million net of expenses) through the issue of 95 million shares at the Placing Price of 17 pence per Placing Share.
Participants in the Placing will be contacted by N+1 Singer as soon as practicable today to confirm their allocations. A further announcement will be made in due course confirming final details of the Placing.
It is expected that settlement of the Placing Shares and Admission will take place at 8.00 a.m. on 7 August 2020. The Placing is conditional upon, among other things, Admission becoming effective on or before 8.00 a.m. on 7 August 2020 or such later date (being no later than 10 August 2020) as N+1 Singer and the Company may agree. The Placing is also conditional upon the Placing Agreement not being terminated in accordance with its terms.
Save as otherwise defined, capitalised terms used in this announcement have the meanings given to them in the announcement released by the Company at 5.13 p.m. on 4 August 2020.
For further information, please contact:
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0)20 7213 0880 |
N+1 Singer (Joint Corporate Broker and Sole bookrunner) | Tel: +44 (0)20 7496 3000 |
Stifel Nicolaus Europe Limited (Joint Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison | Tel: +44 (0)20 7710 7600 |
Walbrook PR Ltd (Media and Investor Relations) Paul McManus / Lianne Cawthorne | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Mob: 07980 541 893 Mob: 07584 391 303 |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
